Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
8.24
+0.41 (5.31%)
At close: Aug 29, 2025, 4:00 PM
8.00
-0.23 (-2.85%)
After-hours: Aug 29, 2025, 7:50 PM EDT
Cyclacel Pharmaceuticals Employees
Cyclacel Pharmaceuticals had 12 employees as of December 31, 2019. The number of employees decreased by 2 or -14.29% compared to the previous year.
Employees
12
Change (1Y)
-2
Growth (1Y)
-14.29%
Revenue / Employee
$833
Profits / Employee
-$535,667
Market Cap
18.44M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2019 | 12 | -2 | -14.29% |
Dec 31, 2018 | 14 | 2 | 16.67% |
Dec 31, 2017 | 12 | -1 | -7.69% |
Dec 31, 2016 | 13 | -3 | -18.75% |
Dec 31, 2015 | 16 | -2 | -11.11% |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CYCC News
- 18 days ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 27 days ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 6 weeks ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 7 weeks ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 7 weeks ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire
- 3 months ago - CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - GlobeNewsWire